Recent Finacing
Recent Raise
Comanche Biopharma develops CBP-4888, a fixed-dose combination of two siRNA duplexes that reduce placental sFlt1 to treat preeclampsia; completed Phase 1 in women and plans pregnant-patient trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Comanche Biopharma.
